No official announcement has been made yet quite yet, but various reports confirm that Daisuke Matsuzaka will undergo Tommy John elbow surgery next week.
That means he’s finished for this season and will likely miss most or perhaps even all of 2012, which is the final year of his six-year contract with the Red Sox signed in December of 2006.
Between the posting fee to win his exclusive negotiations rights and the six-year contract Boston made a total investment of $103 million in Matsuzaka. What did they get for that money?
Your mileage may vary, of course, but to my eyes Matsuzaka has had one very good season (2008), two decent seasons (2007, 2010), and two injury wrecked and/or terrible seasons (2009, 2011). Add it all up and he logged 623 innings spread over 105 starts and one relief appearance, posting a 4.25 ERA and 568/301 K/BB ratio while opponents hit .242 with a .720 OPS off him.
Basically he was a solid mid-rotation starter with durability issues, starting 32, 29, 12, 25, and 7 games (plus whatever he contributes next season) with an ERA that was 5-10 percent better than the league average once you adjust for Fenway Park.
According to Fan Graphs’ player evaluation system that performance was worth about $44 million and Matsuzaka also had a 4.79 ERA in seven postseason starts, so let’s bump that up to around $50 million. There are probably also plenty of off-field factors involved in his overall value to the team, but strictly in terms of on-field performance for a six-year, $103 million investment the Red Sox received approximately $50 million worth of value in the form of one good season, two decent seasons, and two (and likely three) bad seasons.
It’s been a miserable weekend for Nationals’ outfielder Adam Eaton, who stumbled over first base and injured his leg while running out an infield single in Friday’s 4-3 win over the Mets. While the team officially placed the outfielder on the 10-day disabled list with a left knee strain on Saturday, FOX Sports’ Ken Rosenthal reports that Eaton has been diagnosed with a torn ACL in his left knee and is expected to miss the remainder of the 2017 season. The team has yet to confirm the diagnosis or announce a definite timetable for the 28-year-old’s return, perhaps due to extended evaluations by Eaton’s orthopedic doctor:
The Nationals appear to have several outfield options with Eaton on the disabled list, though they have not pinned down a long-term solution. Center fielder Michael Taylor replaced Eaton on the field during the tail end of Friday’s game, and returned on Saturday to man center and bat second in the lineup. The club also promoted top outfield prospect Rafael Bautista, who slashed .291/.325/.354 with five doubles and a .680 OPS through 19 games in Triple-A Syracuse this season. He’ll assume Eaton’s roster spot and looks to be available for a backup role in the outfield going forward.
Last we heard from Shelby Miller, the Diamondbacks’ right-hander was contemplating Tommy John surgery for a partial UCL tear in his right elbow. Now, he appears to have decided to go through with the procedure.
Miller decided to skip Tommy John alternatives like plasma-rich platelet injections or stem cell treatment, which have been used to varying degrees of success by other major league pitchers with similar injuries. The surgery will set him back an estimated 12-18 months, FanRag Sports’ Tommy Stokke reports, which puts Miller’s estimated return date somewhere in 2018 if all goes well.
The 26-year-old starter was off to a rocky start this season, posting a 2-2 record and 4.09 ERA through 22 innings and striking out just 20 of 99 batters faced. This was his sophomore campaign in Arizona after muddling through the 2016 season with a 3-12 record, 6.15 ERA and 0.5 fWAR over 101 innings with the club.